Modern role of magnetic resonance and spectroscopy in the imaging of prostate cancer

Urologic Oncology: Seminars and Original Investigations

Volumn 29, Issue 1, 2011, Pages 12-20

  Sciarra, Alessandro ^a   Panebianco, Valeria ^a   Salciccia, Stefano ^a   Cattarino, Susanna ^a   Lisi, Dino ^a   Gentilucci, Alessandro ^a   Alfarone, Andrea ^a   Mariotti, Gianna ^a   Passariello, Roberto ^a   Gentile, Vincenzo ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Imaging; Magnetic resonance; Prostate neoplasm; Spectroscopy

Indexed keywords

CANCER DIAGNOSIS; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURGERY; CLINICAL ASSESSMENT; CONTRAST ENHANCEMENT; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE COURSE; EARLY DIAGNOSIS; HORMONAL THERAPY; HUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROSTATE CANCER; PROTON NUCLEAR MAGNETIC RESONANCE; REVIEW; SENSITIVITY AND SPECIFICITY; TREATMENT INDICATION; TUMOR BIOPSY;

HUMANS; MAGNETIC RESONANCE IMAGING; MAGNETIC RESONANCE SPECTROSCOPY; MALE; PROSTATIC NEOPLASMS;

EID: 78650678186     PISSN: 10781439     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.urolonc.2009.06.001     Document Type: Review

References (48)

1. Aus G., Abbou C.C., Bolla M., et al. EAU guidelines on prostate cancer. Eur Urol 2005, 48:546-551.
2. Heidenreich A., Aus G., Bolla M., et al. EAU guideline on prostate cancer. Eur Urol 2008, 53:68-80. European Association of Urology.
3. Choyke P.L. Imaging of prostate cancer. Abdm Imaging 1995, 20:505-515.
4. Stamey T. Making the most out of six systematic sextant biopsies. Urology 1995, 45:2-12.
5. Hernandez J., Thompson I.M. Prostate-specific antigen: A review of the validation of the most commonly used cancer biomarker. Cancer 2004, 101:894-904.
6. Sciarra A., Panebinanco V., Salciccia S., et al. Role of dynamic contrast-enhanced magnetic resonance imaging and proton MR spectroscopic imaging in the detection of local recurrence after radical prostatectomy for prostate cancer. Eur Urol 2008, 54:589-600.
7. Kirkham A.P., Emberton M., Allen C. How good is MRI at detecting and characterizing cancer within the prostate?. Eur Urol 2006, 50:1163-1175.
8. Anastasiadis A.G., Lichy M.P., Nagele U., et al. MRI-guided biopsy of the prostate increases diagnostic performance in men with elevated or increasing PSA levels after previous negative TRUS biopsies. Eur Urol 2006, 50:738-749.
9. Rajesh A., Coakley F.V., Khrhanewicz J. 3D spectroscopic imaging in the evaluation of prostate cancer. Clin Radiol 2007, 62:921-929.
10. Comet-Batle J., Vilanova-Busquests J.C., Saladiè-Roig J.M., et al. The Value of endorectal MRI in the early Diagnosis of prostate cancer. Eur Urol 2003, 44:201-208.
11. Hricak H. MR imaging and MR spectroscopic imaging in the pretreatment evaluation of prostate cancer. Br J Radiol 2005, 78:103-111.
12. Heuck A., Scheidler J., Sommer B., et al. MR imaging of prostate cancer. Radiologe 2003, 43:464-473.
13. Hersh M.R., Knapp E.L., Choi J. Newer imaging modalities to assess tumor in the prostate. Cancer Control 2004, 11:353-357.
14. Rajesh A., Coakley F.V. MR imaging and MR spectroscopic imaging of prostate cancer. Magn Reson Imaging Clin N Am 2004, 12:557-579.
15. Casciani E., Gualdi G. Prostate cancer: Value of magnetic resonance spectroscopy 3D chemical shift imaging. Abdom Imaging 2006, 31:490-499.
16. Shukla-Dave A., Hricak H., Eberhardt S.C., et al. Chronic prostatitis: MR imaging and 1H MR spectroscopic imaging findings-initial observations. Radiology 2004, 231:717-724.
17. Casciani E., Polettini E., Bertini L., et al. Granulomatous prostatitis: A pitfall in endorectal MR imaging and 3D MR spectroscopic imaging. Eur J Radiol 2005, 54:111-114.
18. Kaji Y., Kurhanewicz J., Hricak H., et al. Localizing prostate cancer in the presence of post-biopsy changes on MR images: Role of proton MR spectroscopic imaging. Radiology 1998, 206:785-790.
19. Sciarra A., Salciccia S., Panebianco V. Proton spectroscopic and dynamic contrast-enhanced magnetic resonance: A modern approach in prostate cancer imaging. Eur Urol 2008, 54:485-488.
20. Manenti G., Squillaci E., Carlani M., et al. Magnetic resonance imaging of the prostate with spectroscopic imaging using a surface coil. Initial clinical experience. Radiol Med (Torino) 2006, 111:22-32.
21. Bloch B.N., Furman-Haran E., Helbich T.H., et al. Prostate cancer: Accurate determination of extracapsular extension with high-spatial-resolution dynamic contrast-enhanced and T2-weighted MR imaging initial results. Radiology 2007, 245:176-185.
22. Yuen J.S., Thng C.H., Tan P.H., et al. Endorectal magnetic resonance imaging and spectroscopic for the detection of tumor foci in men with prior negative transrectal ultrasound prostate biopsy. J Urol 2004, 171:1482-1486.
23. Amsellem-Ouazana D., Younse P., Conquy S., et al. Negative prostatic biopsies in patients with High risk of prostate cancer. Eur Urol 2005, 47:582-586.
24. Horn J.J., Coakley F.V., Simko J.P., et al. HGPIN in patients with prostate cancer; MR and MR spectroscopic imaging features: Initial experience. Radiology 2007, 242:483-489.
25. Cookson M.S., Fleshner N.E., Soloway S.M., et al. Correlation between Gleason score of needle biopsy and radical prostatectomy specimens: Accuracy and clinical implications. J Urology 1997, 157:559-562.
26. Steinberg M.D., Sauvageot J., Piantadosi S., et al. Correlation of prostate needle biopsy and radical prostatectomy Gleason grade in academic and community settings. Am J Surg Pathol 1997, 21:566-576.
27. Zakian K.L., Sircar K., Hricak H., et al. Correlation of proton MR spectroscopic imaging with Gleason score based on step-section pathologic analysis after radical prostatectomy. Radiology 2005, 234:804-814.
28. Smith J.A., Scardino P.T., Resnick M.I., et al. Transrectal ultrasound versus digital rectal examination for the staging of carcinoma of the prostate: Results of a prospective, multi-institutional trial. J Urol 1997, 157:902-906.
29. Cornud F., Belin X., Piron D., et al. Color Doppler-guided prostate biopsies in 591 patients with an elevated serum PSA level: Impact on Gleason score for nonpalpable lesions. Urology 1997, 49:709-715.
30. Wilkinson B.A., Hamdy F.C. State-of-the-art staging in prostate cancer. BJU Int 2001, 87:423-430.
31. Jager J.G., Ruijter E.T., van de Kaa C.A., et al. Local staging of prostate cancer with endorectal MR imaging: Correlation with histopathology. AJR 1996, 166:845-850.
32. Wang L., Hricak H., Kattan K.W., et al. Prediction of organ confined prostate cancer. Incremental value of MR imaging and MR spectroscopic imaging to staging nomograms. Radiology 2006, 238:597-603.
33. Yu K.K., Scheidler J., Hricak H., et al. Prostate cancer: Prediction of extracapsular extension with endorectal MR imaging and three-dimensional proton MR spectroscopic imaging. Radiology 1999, 213:481-488.
34. Seitz M., Shukla-Dave A., Bjartell A., et al. Functional magnetic resonance imaging in prostate cancer. Eur Urol 2009, [Epub ahead of print].
35. Yan Y., Carvalhal G.F., Catalona W.J., et al. Primary treatment choices for men with clinically localized prostate carcinoma detected by screening. Cancer 2000, 88:1122-1130.
36. Sakai I., Harada K., Kurahashi T., et al. Usefulness of the nadir value of serum prostate-specific antigen measured by an ultrasensitive assay as a predictor of biochemical recurrence after radical prostatectomy for clinically localized prostate cancer. Urol Int 2006, 76:227-231.
37. Neulander E.Z., Soloway M.S. Failure after radical prostatectomy. Urology 2003, 61:30-36.
38. Prando A., Kurhanewicz J., Borges A.P., et al. Prostatic biopsy directed with endorectal MR spectroscopic imaging findings in patients with elevated prostate specific antigen levels and prior negative biopsy findings: Early experience. Radiology 2005, 236:903-910.
39. Futterer J.J., Heijmink S.W., Scheenen T.W., et al. Prostate cancer localization with dynamic contrast-enhanced MR imaging and proton MR spectroscopic imaging. Radiology 2006, 241:449-458.
40. Shekarriz B., Upadhyay J., Wood D.P. Vesicourethral anastomosis biopsy after radical prostatectomy: Predictive value of prostate-specific antigen and pathologic stage. Urology 1999, 54:1044-1048.
41. Silverman J.M., Krebs T.L. MR imaging evaluation with a transrectal surface coil of local recurrence of prostatic cancer in men who have undergone radical prostatectomy. AJR Am J Roentgenol 1997, 168:379-385.
42. Raj G.V., Partin A.W., Polascik T.J. Clinical utility of indium 111-capromab pendetide Immunoscintigraphy in the detection of early, recurrent prostate carcinoma after radical prostatectomy. Cancer 2002, 94:987-996.
43. Hricak H., Wang L., Wei D.C., et al. The role of preoperative endorectal magnetic resonance imaging in the decision regarding whether to preserve or resect neurovascular bundles during radical retropubic prostatectomy. J Urol 2005, 173:416.
44. Lee S.E., Hong S.K., Han J.H., et al. Significance of neurovascular bundle formation observed on preoperative magnetic resonance imaging regarding postoperative erectile function after nerve-sparing radical retropubic prostatectomy. Urology 2007, 69:510-514.
45. Panebianco V., Sciarra A., Salciccia S., et al. 2D and 3D T2-weighted MR sequences for the assessment of neurovascular bundle changes after nerve-sparing radical retropubic prostatectomy with erectile function correlation. Eur Radiol 2009, 19:220-229.
46. D'Amico A.V., Halabi S., Tempany C., et al. Tumor volume changes on 1.5 Tesla endorectal MRI during neoadjuvant androgen suppression therapy for higher risk prostate cancer and recurrence in men treated using radiation therapy results of the phase II CALGB 9682 study. Int J Radiat Oncol Biol Phys 2008, 71:9-15.
47. Mueller-Lisse U.G., Swanson M.G., Vigneron D.B., et al. Hormone ablation of localized prostate cancer: Time dependent therapy effects on prostate metabolism detected by 3D 1H MR spectroscopy. Magn Reson Med 2001, 46:49-57.
48. Sciarra A., Panebianco V., Ciccariello M., et al. Complete response to the combination therapy with androgen blockade and somatostatin analogue in a patient with advanced prostate cancer. Eur Urol 2008, 53:652-655.